Microbot Medical Inc. balance sheet MBOT

As of Jun 30, 2026, Microbot Medical Inc. had total assets of $73.4 million and total liabilities of $4.4 million. Total assets were up 121.4% from a year earlier. Stockholders' equity was $68.9 million. It held $67.4 million in cash and investments against $876,000 of total debt, net cash of $66.5 million. The current ratio, current assets divided by current liabilities, was 18.56.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
FY 2016
Dec 31, 2016
Assets
Cash
3
-22.8%
4
+25.6%
3
+26.2%
2
+1.1%
2
-81.9%
13
-31.3%
20
-31.7%
29
+449.3%
5
-51.4%
11
+298.2%
3
+519.9%
Short-term investments
64
+124.6%
75
+3069.8%
2
-39.9%
4
-32.0%
6
+188.1%
2
-60.0%
5
+98.3%
3
—
—
—
Cash and investments
67
+106.2%
79
+1336.8%
5
-14.3%
6
-22.2%
8
-47.1%
15
-37.1%
25
-21.2%
31
+497.4%
5
-51.4%
11
+298.2%
3
+519.9%
Receivables
0
—
—
—
—
—
—
—
—
—
—
Inventory
3
1
—
—
—
—
—
—
—
—
—
Total current assets
72
+119.4%
80
+1271.7%
6
-26.5%
8
-10.1%
9
-44.5%
16
-37.1%
25
-29.7%
36
+516.3%
6
-46.7%
11
+229.7%
3
+575.2%
Property and equipment, net
0
+321.3%
0
+16.2%
0
-45.2%
0
-33.9%
0
-9.4%
0
-2.8%
0
+10.1%
0
-12.0%
0
+187.8%
0
+69.8%
0
+39.5%
Total assets
73
+121.4%
82
+1252.1%
6
-27.6%
8
-12.7%
10
-43.1%
17
-36.2%
26
-29.2%
37
+509.6%
6
-44.7%
11
+227.2%
3
+536.7%
Liabilities and equity
Accounts payable
1
+73.2%
1
—
—
0
-58.4%
0
+1.5%
0
-3.2%
0
-54.9%
1
+707.7%
0
-84.8%
1
+1948.0%
Total current liabilities
4
+42.6%
3
+39.1%
2
-35.0%
4
+83.0%
2
+4.3%
2
+47.5%
1
-72.1%
5
+1.4%
5
+801.5%
1
-32.6%
1
+350.0%
Total liabilities
4
+60.0%
4
+59.5%
3
-34.6%
4
+70.2%
2
-5.8%
2
+21.1%
2
-64.7%
6
+17.4%
5
+756.1%
1
-52.6%
1
+179.7%
Stockholders' equity
69
+127.1%
78
+2097.0%
4
-21.6%
5
-38.2%
7
-49.3%
14
-40.8%
24
-22.9%
32
+2271.4%
1
-86.7%
10
+489.2%
2
+2750.0%
Debt
Lease liabilities
1
+487.9%
1
+679.3%
0
-51.9%
0
-50.0%
0
-32.1%
1
-16.4%
1
-10.0%
1
—
—
—
Total debt
1
+487.9%
1
+679.3%
0
-51.9%
0
-50.0%
0
-32.1%
1
-16.4%
1
-10.0%
1
—
—
—
Net cash
66
+104.4%
78
+1350.4%
5
-12.9%
6
-20.5%
8
-47.7%
15
-37.9%
24
-21.6%
30
—
—
—
Ratios
Current ratio
18.56x
23.33x
2.37x
2.09x
4.26x
8.00x
18.78x
7.45x
1.23x
20.70x
4.23x
Debt to equity
0.01x
0.01x
0.03x
0.05x
0.06x
0.05x
0.03x
0.03x
—
—
—
Return on equity
-23.70%
-16.95%
-324.16%
-238.61%
-180.66%
-78.67%
-37.72%
-22.98%
-545.86%
-75.95%
-569.75%
Return on assets
-22.27%
-16.12%
-189.74%
-128.98%
-138.07%
-67.47%
-34.89%
-19.52%
-119.21%
-68.87%
-286.91%
Book value per share
1.03
1.15
0.18
0.38
0.92
2.02
3.42
4.39
0.44
4.96
0.11
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
MBOT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Hingham, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
883975
Former names
Microbot Medical Inc. (until Nov 3, 2026); STEMCELLS INC (until Nov 15, 2016); CYTOTHERAPEUTICS INC/DE (until May 15, 2000)

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.